Abstract
Lung cancer is a disease with very high morbidity and mortality rate. In spite of aggressive treatment modalities, the long- term survival is very low, and these treatments have many toxic adverse effects. Immunological therapies or briefly “immunotherapy” is a promising new therapeutic modality for lung cancer; it can be in the form of active immunization (cancer vaccines), passive immunization (adoptive cell therapy or antibody-based treatment) or immunostimulation.
Keywords: Lung cancer, immunotherapy, vaccine, antibody-based treatment, cetuximab, bevacizumab, panitumumab, matuzumab, pertuzumab, transtuzumab, erlotinin, paclitaxel, carboplatin, gemtuzumab, GVAX, MUC1, MAGE-A3, TG4010.
Related Journals
Related Books
Andrology: Current and Future Developments
Male Infertility: An Integrative Manual of Western and Chinese Medicine
Awake Thoracic Surgery
The Anatomical Foundations of Regional Anesthesia and Acute Pain Medicine Macroanatomy Microanatomy Sonoanatomy Functional anatomy
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents
Frontiers in Anti-infective Agents